Vox Sanguinis

Papers
(The H4-Index of Vox Sanguinis is 20. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Collecting and evaluating convalescent plasma for COVID‐19 treatment: why and how?110
ABO blood group and COVID‐19: a review on behalf of the ISBT COVID‐19 Working Group103
Impact of COVID‐19 on blood centres in Zhejiang province China102
Inactivation of severe acute respiratory syndrome coronavirus 2 in plasma and platelet products using a riboflavin and ultraviolet light‐based photochemical treatment84
Post‐donation COVID‐19 identification in blood donors71
Points to consider in the preparation and transfusion of COVID‐19 convalescent plasma58
The impact of the SARS‐CoV‐2 outbreak on the safety and availability of blood transfusions in Italy39
Guidance for the procurement of COVID‐19 convalescent plasma: differences between high‐ and low‐middle‐income countries39
Coronavirus disease 2019 (COVID‐19) and decrease in blood donation: experience of Iranian Blood Transfusion Organization (IBTO)38
Impact of the COVID‐19 pandemic on blood supply and demand in the WHO African Region37
Operational protocol for donation of anti‐COVID‐19 convalescent plasma in Italy34
Blood group ABO polymorphism inhibits SARS‐CoV‐2 infection and affects COVID‐19 progression29
Blood donation in times of crisis: Early insight into the impact of COVID‐19 on blood donors and their motivation to donate across European countries29
Pivotal role of convalescent plasma in managing emerging infectious diseases27
Neonatal red blood cell transfusion26
The risk to future pregnancies of transfusing Rh(D)‐negative females of childbearing potential with Rh(D)‐positive red blood cells during trauma resuscitation is dependent on their age at transfusion26
Clinical use of Convalescent Plasma in the COVID‐19 pandemic: a transfusion‐focussed gap analysis with recommendations for future research priorities26
Early experience with convalescent plasma as immunotherapy for COVID‐19 in China: Knowns and unknowns26
COVID‐19 convalescent plasma therapy: hit fast, hit hard!21
Use of COVID‐19 convalescent plasma in low‐ and middle‐income countries: a call for ethical principles and the assurance of quality and safety20
Understanding the role of therapeutic plasma exchange in COVID‐19: preliminary guidance and practices20
Research initiatives of blood services worldwide in response to the covid‐19 pandemic20
Washed red cells: theory and practice20
0.12324500083923